bortezomib

E241388

antineoplastic agent antineoplastic immunomodulating agent chemotherapy drug peptidyl boronic acid proteasome inhibitor small molecule drug

Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.

Try in SPARQL Jump to: Surface forms Disambiguation Statements Elicitation Referenced by

All labels observed (4)

Label	Occurrences
Velcade	5
bortezomib canonical	4
Bortezomib Accord	1
Bortezomib Teva	1

How this entity was disambiguated

This entity first appeared as the object of triple T2190710 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.

NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07

Target entity: bortezomib
Context triple: [Darzalex, usedInCombinationWith, bortezomib]

A. Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
B. Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
C. Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
D. Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
E. Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
F. None of above. chosen
G. Unsure - the case is ambiguous/there is not enough information to decide.

NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07

Target entity: bortezomib
Target entity description: Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.

A. Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
B. Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
C. Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
D. Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
E. Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
F. None of above. chosen

Statements (55)

Predicate	Object
instanceOf	antineoplastic agent ⓘ antineoplastic immunomodulating agent ⓘ chemotherapy drug ⓘ peptidyl boronic acid ⓘ proteasome inhibitor ⓘ small molecule drug ⓘ
adverseEffect	anemia ⓘ constipation ⓘ diarrhea ⓘ fatigue ⓘ herpes zoster reactivation ⓘ nausea ⓘ neutropenia ⓘ peripheral neuropathy ⓘ thrombocytopenia ⓘ
developer	Johnson & Johnson ⓘ Millennium Pharmaceuticals ⓘ
firstApprovalAgency	U.S. Food and Drug Administration ⓘ linked to: Food and Drug Administration
firstApprovalYear	2003 ⓘ
hasATCCode	L01XX32 ⓘ
hasBioavailability	100% (intravenous) ⓘ
hasCASNumber	179324-69-7 ⓘ
hasEffect	disrupts protein homeostasis in cancer cells ⓘ induces apoptosis in malignant plasma cells ⓘ
hasEliminationHalfLife	approximately 9 to 15 hours ⓘ
hasMechanismOfAction	inhibits chymotrypsin-like activity of the proteasome ⓘ reversible inhibitor of the 26S proteasome ⓘ
hasMolecularFormula	C19H25BN4O4 ⓘ
hasMolecularWeight	384.24 g/mol ⓘ
hasTradeName	Bortecad ⓘ Bortezomib Accord ⓘ linked to: bortezomib Bortezomib Teva ⓘ linked to: bortezomib Velcade ⓘ linked to: bortezomib
indication	mantle cell lymphoma ⓘ multiple myeloma ⓘ previously untreated mantle cell lymphoma ⓘ previously untreated multiple myeloma ineligible for transplant ⓘ relapsed multiple myeloma ⓘ
legalStatusEU	prescription only ⓘ
legalStatusUS	prescription only ⓘ
metabolism	primarily hepatic ⓘ
metabolizingEnzyme	CYP1A2 ⓘ CYP2C19 ⓘ CYP3A4 ⓘ
oftenUsedWith	cyclophosphamide ⓘ dexamethasone ⓘ lenalidomide ⓘ melphalan ⓘ linked to: cyclophosphamide prednisone ⓘ
pregnancyCategoryUS	D ⓘ
proteinBinding	high ⓘ
routeOfAdministration	intravenous ⓘ subcutaneous ⓘ
target	26S proteasome beta 5 subunit ⓘ
UNII	Q9Y238A5X4 ⓘ

How these facts were elicited

Referenced by (11)

Full triples — surface form annotated when it differs from this entity's canonical label.

Darzalex → usedInCombinationWith → bortezomib ⓘ

bortezomib → hasTradeName → Velcade ⓘ

linked to: bortezomib

bortezomib → hasTradeName → Bortezomib Accord ⓘ

linked to: bortezomib

bortezomib → hasTradeName → Bortezomib Teva ⓘ

linked to: bortezomib

daratumumab → usedInCombinationWith → bortezomib ⓘ

Bortecad → isBrandOf → bortezomib ⓘ

Millennium Pharmaceuticals → developed → Velcade ⓘ

linked to: bortezomib

bortezomib → tradeName → Velcade ⓘ

subject linked to: Millennium Pharmaceuticals

linked to: bortezomib

Velcade → activeIngredient → bortezomib ⓘ

subject linked to: Millennium Pharmaceuticals

Millennium Pharmaceuticals → knownFor → Velcade ⓘ

linked to: bortezomib

Millennium Pharmaceuticals → regulatoryApprovalFor → Velcade ⓘ

linked to: bortezomib

All labels observed (4)

How this entity was disambiguated Show

Statements (55)

How these facts were elicited Show

Referenced by (11)

How this entity was disambiguated

How these facts were elicited